U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C25H23N5O2S2.ClH
Molecular Weight 526.073
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BMS-214662 HYDROCHLORIDE

SMILES

Cl.O=S(=O)(N1CC2=C(C=CC(=C2)C#N)N(CC3=CN=CN3)C[C@H]1CC4=CC=CC=C4)C5=CC=CS5

InChI

InChIKey=LBPFLNDUCNNGPS-GNAFDRTKSA-N
InChI=1S/C25H23N5O2S2.ClH/c26-13-20-8-9-24-21(11-20)15-30(34(31,32)25-7-4-10-33-25)23(12-19-5-2-1-3-6-19)17-29(24)16-22-14-27-18-28-22;/h1-11,14,18,23H,12,15-17H2,(H,27,28);1H/t23-;/m1./s1

HIDE SMILES / InChI
Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C25H23N5O2S2
Molecular Weight 489.612
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Bristol-Myers Squibb developed BMS-214662 as potent and selective farnesyl transferase inhibitor with potent antitumor activity. BMS-214662 participated in phase II trials in the US for pancreatic, head and neck, lung and colorectal cancers. However, further information is not available.

Originator

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
 0.7 nM [IC50]
PubMed

PubMed

TitleDatePubMed
Discovery of (R)-7-cyano-2,3,4, 5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3- (phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine (BMS-214662), a farnesyltransferase inhibitor with potent preclinical antitumor activity.
2000 Oct 5
Targeting RAS signalling pathways in cancer therapy.
2003 Jan
Farnesyltransferase inhibitor BMS-214662 induces apoptosis in myeloma cells through PUMA up-regulation, Bax and Bak activation, and Mcl-1 elimination.
2005 Jun
Design, Synthesis and Evaluation of Novel 1-(Substituted Acetyl)-4-(10-Bromo-8-Chloro-5,6-Dihydro-11H-Benzo[5,6]Cyclohepta[1,2-B]Pyridine-11-Ylidene)piperidines as Antitumor Agents and Farnesyl Protein Transferase Inhibitors.
2010 Sep
Patents

Patents

06949642
3

Sample Use Guides

In Vivo Use Guide
Patients were treated every week as tolerated with i.v. paclitaxel (fixed dose, 80 mg/m(2)/wk) administered over 1 h followed by i.v. BMS-214662 (escalating doses, 80-245 mg/m(2)/wk) over 1 h starting 30 min after completion of paclitaxel.
Route of Administration: Intravenous
Substance Class Chemical
Created
by admin
on Sat Dec 16 08:18:27 GMT 2023
Edited
by admin
on Sat Dec 16 08:18:27 GMT 2023
Record UNII
2ZRT8VWQ9J
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BMS-214662 HYDROCHLORIDE
Common Name English
1H-1,4-BENZODIAZEPINE-7-CARBONITRILE, 2,3,4,5-TETRAHYDRO-1-(1H-IMIDAZOL-5-YLMETHYL)-3-(PHENYLMETHYL)-4-(2-THIENYLSULFONYL)-, HYDROCHLORIDE (1:1), (3R)-
Systematic Name English
Code System Code Type Description
PUBCHEM
44189294
Created by admin on Sat Dec 16 08:18:27 GMT 2023 , Edited by admin on Sat Dec 16 08:18:27 GMT 2023
PRIMARY
FDA UNII
2ZRT8VWQ9J
Created by admin on Sat Dec 16 08:18:27 GMT 2023 , Edited by admin on Sat Dec 16 08:18:27 GMT 2023
PRIMARY
CAS
195981-08-9
Created by admin on Sat Dec 16 08:18:27 GMT 2023 , Edited by admin on Sat Dec 16 08:18:27 GMT 2023
PRIMARY
DRUG BANK
DBSALT002163
Created by admin on Sat Dec 16 08:18:27 GMT 2023 , Edited by admin on Sat Dec 16 08:18:27 GMT 2023
PRIMARY
Related Record Type Details
Structure of BMS-214662
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of BMS-214662
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966